Covishield: SII refutes adverse reaction claim, seeks Rs 100-cr in damages
The complainant also demanded that the ongoing trials in India of the vaccine candidate be immediately halted. Vaccine major Serum Institute of India (SII) on Sunday strongly refuted an allegation that Covishield, the vaccine candidate for Covid-19, which is in the third phase of human trials in India, triggered adverse reaction in a Chennai-based 40-year-old … Read more